Endocrine Abstracts

Undifferentiated thyroid carcinomas are extremely aggressive and currently lack effective treatment. Aberrant RAS-ERK signaling, triggered mainly by BRAF and RAS mutations, is responsible for the occurrence and progression of most thyroid carcinomas, which led to the clinical use of small kinase inhibitors targeting kinases of the pathway. The results were disappointing, because of the emergence of resistance and high-associated toxicity. A more specific approach, targeting si...